Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Marstacimab · Hympavzi

Monoclonal antibody · Antagonist of Tissue factor pathway inhibitor (TFPI) · developed by Pfizer

Approved FDA, Oct 2024
PFE Developer
1 Registered trials

What is Marstacimab?

Marstacimab is a human monoclonal IgG1 antibody that binds the Kunitz domain 2 of tissue factor pathway inhibitor (TFPI), neutralizing its activity to enhance coagulation. It is studied in hemophilia A or B.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Hympavzi, PF-06741086
Drug type
Monoclonal antibody
Targets
Tissue factor pathway inhibitor (TFPI)
Mechanism
Antagonist of Tissue factor pathway inhibitor (TFPI)
Pathways
extrinsic coagulation cascade, thrombin generation
Therapy area
Hematology
Developer
Pfizer Inc (PFE)
FDA status
Approved as Hympavzi (October 11, 2024), BLA761369 · FDA label
UNII
0UB3OA67O7

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07923981 Phase 3 Hemophilia A or B Recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hemophilia A or B

Other drugs acting on TFPI

More from Pfizer

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Marstacimab

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.